1.070SEK-4.29%Mkt Cap: 147.12M SEKP/E: —Last update: 2026-06-01
Diamyd Medical AB (publ) develops precision medicine therapies for the treatment of autoimmune diabetes. The company develops Diamyd, an antigen-specific immunotherapy, which is in phase III clinical trial for the treatm…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap147.12M SEK
Enterprise Value-37.00M SEK
Revenue (TTM)362.00K SEK
Gross Profit-3.71M SEK
Net Income (TTM)-169.78M SEK
Revenue/Share0.0030 SEK
Last Price1.070 SEK
Fiscal Year EndAug 2025
MR QuarterFeb 2026
Employees41
CountrySE
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-1.45
PEG—
EV/EBITDA0.18
EV/Revenue-102.22
P/S424.65
P/B0.91
EPS (TTM)-1.30
EPS (Forward)—
52W Range
0.89601% of range17.88
52W High17.88 SEK
52W Low0.8960 SEK
Profitability
Gross Margin0.00%
Oper. Margin-65680.80%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-60.64%
ROA-59.98%
Growth
Revenue Growth15.10%
Earnings Growth—
Cash Flow & Leverage
Operating CF-162.65M SEK
CapEx (TTM)—
FCF Margin-28614.43%
FCF Yield-70.41%
Net Debt-190.73M SEK
Net Debt/EBITDA0.95
Balance Sheet
Debt/Equity—
Current Ratio4.83
Quick Ratio4.74
Book Value/Sh1.235 SEK
Cash/Share1.387 SEK
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 SEK
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating0.0 (Hold)
Target (Mean)1.550 SEK
Target Range1.550 SEK – 1.550 SEK
# Analysts1
Ownership
Shares Out.134.00M
Float118.35M
Insiders22.96%
Institutions6.28%
Technical
SMA 502.842 (-62.3%)
SMA 2009.774 (-89.1%)
Beta2.33
S&P 52W Chg27.70%
Avg Vol (30d)2.10M
Avg Vol (10d)1.14M
Technical Indicators
RSI (14)26.1
MACD-0.5869
MACD Signal-0.8148
MACD Hist.+0.2279
BB Upper1.279 SEK
BB Middle1.167 SEK
BB Lower1.055 SEK
BB Width19.17%
ATR (14)0.1932 SEK
Vol Ratio (20d)0.39x